# Scalp cooling therapy in chemotherapy-induced alopecia: addressing variability in cooling duration and efficacy

**Authors:** Lily Kaufman, Lilia Valentic, Lauren Malley, Christina Icksarus, Lucy Rose, Brittany Dulmage

PMC · DOI: 10.1007/s00520-025-10058-y · Supportive Care in Cancer · 2025-11-01

## TL;DR

Scalp cooling therapy helps prevent hair loss during chemotherapy, but its effectiveness varies due to inconsistent cooling times and patient factors.

## Contribution

The paper reviews current practices and proposes strategies to standardize and optimize scalp cooling therapy protocols.

## Key findings

- Pre-cooling durations range from 5–30 minutes and post-cooling from 15 minutes to 4 hours, with limited evidence for longer durations.
- Taxane-based chemotherapy regimens show better hair preservation compared to anthracyclines.
- Portable systems and shorter post-cooling times may improve feasibility and patient tolerance.

## Abstract

Chemotherapy-induced alopecia (CIA) is a distressing side effect of cancer treatment with significant psychosocial consequences. Scalp cooling therapy (SCT) reduces the risk of CIA, but variability in pre- and post-infusion cooling durations limits its standardization and broader implementation. This review aims to examine current practices, identify factors contributing to variation, and explore strategies for optimizing SCT protocols.

We conducted a narrative review of published literature on SCT, including studies evaluating efficacy across chemotherapy regimens, SCT duration, patient factors such as hair type and race, and institutional barriers. We also reviewed studies assessing innovations aimed at reducing chair time and improving feasibility of SCT delivery in diverse clinical settings.

Pre-cooling durations typically range from 5–30 min, while post-cooling times vary from 15 min to 4 h, often without clear evidence for longer durations. Taxane-based regimens show higher hair preservation success compared to anthracyclines. Patient-specific factors (e.g., hair texture, race), staff availability, chair time, and equipment limitations all impact SCT implementation. Portable SCT systems and cooling stations outside the infusion chair have been proposed to improve workflow. Limited data suggest shorter post-cooling may be equally effective and better tolerated.

SCT is an effective intervention for CIA, but wide variation in implementation presents challenges. Standardizing cooling durations based on evidence and patient-centered considerations is essential to improve SCT access, patient satisfaction, and healthcare efficiency. Further research is needed to evaluate shortened protocols, portable systems, and pharmacologic adjuncts that may enhance the feasibility and effectiveness of SCT.

## Linked entities

- **Chemicals:** doxorubicin (PubChem CID 31703)
- **Diseases:** chemotherapy-induced alopecia (MONDO:0005483), cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** alopecia (MESH:D000505), cancer (MESH:D009369), CIA (MESH:D000084202)
- **Chemicals:** Taxane (MESH:C080625), anthracyclines (MESH:D018943)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12578718/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12578718/full.md

---
Source: https://tomesphere.com/paper/PMC12578718